Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
-
December 27, 2018
EISAI TO SUPPORT TSUNAMI RELIEF EFFORTS IN INDONESIA
-
December 17, 2018
Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3鈥檚 RNA Splicing Platform
-
December 17, 2018
EISAI SIGNS COLLABORATION AGREEMENT FOR ANTI-OBESITY AGENT LORCASERIN IN BRAZIL WITH EUROFARMA
-
December 12, 2018
GARDP, Eisai and Takeda announce partnership in the search for new antibiotics
First multi-actor partnership tests chemical compounds for antibacterial activity
-
December 6, 2018
EISAI AND UCL COMMENCE PREPARATIONS FOR PHASE I CLINICAL STUDIES IN ALZHEIMER鈥橲 DISEASE FOR NOVEL ANTI-TAU ANTIBODY E2814 DISCOVERED THROUGH JOINT RESEARCH
-
November 29, 2018
MOVICOL庐 Launched in Japan
The First Polyethylene Glycol Preparation for Chronic Constipation in Japan
-
November 28, 2018
PRIMARY ENDPOINT MET IN PHASE III CLINICAL STUDY OF FYCOMPA庐 AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES AIMING FOR SUBMISSION IN JAPAN
-
November 27, 2018
EISAI TO PRESENT NEW RESEARCH ON ERIBULIN (HALAVEN庐) AT 41ST ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
-
November 22, 2018
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT 72ND AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
-
November 14, 2018
EISAI RECEIVES 鈥淚R GRAND PRIX AWARD鈥�
SECOND IR GRAND PRIX AWARD SINCE 2006
-
November 12, 2018
EISAI LAUNCHES LENVIMA庐 (LENVATINIB) IN CHINA
COMMENCES PROVIDING THE FIRST NEW THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN CHINA IN ALMOST A DECADE
-
November 9, 2018
NEW DATA FROM INVESTIGATIONAL STUDY OF LENVIMA庐 (LENVATINIB) AND KEYTRUDA庐 (PEMBROLIZUMAB) COMBINATION IN THREE DIFFERENT TUMOR TYPES PRESENTED AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER鈥橲 33RD ANNUAL MEETING
-
November 8, 2018
Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn鈥檚 Disease Concluded, Research Activities Commence
-
November 8, 2018
EISAI COMMENCES FULL-SCALE OPERATION OF NEW SUZHOU PLANT IN CHINA
STRENGTHENS IN-HOUSE DOMESTIC PRODUCTION SYSTEM IN CHINA
-
October 29, 2018
Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer鈥檚 Disease (CTAD)
Three- and four-year data continued to show reduction in amyloid plaque and to suggest a slowing of the rate of clinical decline in patients
-
October 26, 2018
EISAI PRESENTS NEW DATA ON LEMBOREXANT FOR TREATMENT OF IRREGULAR SLEEP-WAKE RHYTHM DISORDER IN PATIENTS WITH ALZHEIMER鈥橲 DISEASE AT THE 11TH CLINICAL TRIALS IN ALZHEIMER鈥橲 DISEASE CONFERENCE
-
October 25, 2018
EISAI AND BIOGEN ANNOUNCE PRESENTATION OF ADDITIONAL DATA FROM THE PHASE II CLINICAL TRIAL OF BAN2401 IN EARLY ALZHEIMER鈥橲 DISEASE AT THE 2018 CLINICAL TRIALS ON ALZHEIMER鈥橲 DISEASE (CTAD) CONFERENCE
-
October 25, 2018
Notification Regarding Implementation of Voluntary Retirement Program
-
October 25, 2018
EISAI TO PRESENT LATEST DATA ON LENVIMA庐 (LENVATINIB) AND KEYTRUDA庐 (PEMBROLIZUMAB) COMBINATION AND EXPLORATORY RESEARCH ON A STRUCTURALLY NOVEL CLASS OF STING AGONIST AT 33RD SITC ANNUAL MEETING
-
October 23, 2018
APPLICATION SEEKING MANUFACTURING AND MARKETING APPROVAL IN JAPAN SUBMITTED FOR PARKINSON鈥橲 DISEASE TREATMENT SAFINAMIDE
-
October 22, 2018
EISAI AND MSD JAPAN COMMENCE COLLABORATION ON COMMERCIALIZATION ACTIVITIES FOR LENVIMA庐 (LENVATINIB) IN JAPAN
-
October 19, 2018
Discovery of Candidate Compound as Potential Treatment for Parkinson鈥檚 Disease Using iPS Cells
Opening the Way to Establishing New Techniques for Developing Treatments for Neurological Diseases
-
October 18, 2018
EISAI TO PRESENT LATEST DATA ON ALZHEIMER鈥橲 DISEASE / DEMENTIA PIPELINE AT 11TH CLINICAL TRIALS ON ALZHEIMER鈥橲 DISEASE CONFERENCE
ADDITIONAL DATA FROM BAN2401 PHASE II RESULTS TO BE PRESENTED IN SYMPOSIUM SESSION
-
October 17, 2018
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
Long-term efficacy and safety evaluation in patients with insomnia, a sleep-wake disorder, met primary and key secondary efficacy objectives
-
October 16, 2018
EISAI SIGNS COLLABORATION AGREEMENT FOR ANTI-OBESITY AGENT LORCASERIN IN LATIN AMERICA WITH EUROFARMA
-
October 12, 2018
NEW DRUG APPLICATION FOR PERAMPANEL FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES ACCEPTED IN CHINA
-
October 10, 2018
EISAI TO SUPPORT EARTHQUAKE RELIEF EFFORTS IN SULAWESI, INDONESIA
-
October 10, 2018
EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO 2018 CONGRESS
-
October 5, 2018
NEW DATA ON EFFECT OF ANTI-OBESITY AGENT BELVIQ庐 ON PREVENTION AND REMISSION OF TYPE 2 DIABETES PRESENTED AT THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES AND PUBLISHED IN THE LANCET
-
October 1, 2018
FYCOMPA庐 NEWLY APPROVED BY U.S. FDA AS TREATMENT FOR PARTIAL-ONSET SEIZURES IN PEDIATRIC PATIENTS WITH EPILEPSY
-
September 5, 2018
EISAI AND MERCK & CO., INC., KENILWORTH, N.J., U.S.A. ANNOUNCE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) APPROVAL OF LENVIMA庐 (LENVATINIB) FOR TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
First Approval for LENVIMA in China and First New Therapy for the First-line Treatment of Unresectable HCC Approved in China in a Decade
-
September 3, 2018
NOTICE REGARDING PARTIAL LABEL CHANGE FOR VASCULAR EMBOLIZATION DEVICE DC BEAD庐
-
August 29, 2018
LENVIMA庐 (LENVATINIB) CAPSULES APPROVED FOR FIRST-LINE TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN SOUTH KOREA
-
August 29, 2018
Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer鈥檚 Disease Treatment Aducanumab
Data Includes Additional Analyses of Long-Term Extension Phase 1b Study With Titration Cohort at 36 Months and Fixed-Dose Cohorts at 48 Months
-
August 28, 2018
LONG-TERM CARDIOVASCULAR OUTCOMES DATA FOR ANTI-OBESITY AGENT BELVIQ庐 PRESENTED AT THE EUROPEAN SOCIETY OF CARDIOLOGY AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE
-
August 23, 2018
EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR LENVIMA庐 (LENVATINIB) AS FIRST-LINE TREATMENT IN ADULTS WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA
-
August 17, 2018
EISAI AND MERCK & CO., INC., KENILWORTH, N.J., U.S.A. ANNOUNCE FDA APPROVAL OF LENVIMA庐 (LENVATINIB) CAPSULES FOR FIRST-LINE TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
-
July 31, 2018
EISAI SIGNS COLLABORATION AGREEMENT FOR ANTI-OBESITY AGENT LORCASERIN IN CHINA WITH CY BIOTECH
-
July 31, 2018
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA庐 in Combination with KEYTRUDA庐
as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial Carcinoma
-
July 26, 2018
EISAI AND BIOGEN ANNOUNCE DETAILED RESULTS OF PHASE II CLINICAL STUDY OF BAN2401 IN EARLY ALZHEIMER鈥橲 DISEASE AT ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2018
-
July 26, 2018
EISAI AND BIOGEN PRESENT DETAILED RESULTS FROM PHASE II CLINICAL STUDY OF ELENBECESTAT IN MCI AND MILD TO MODERATE ALZHEIMER鈥橲 DISEASE AT ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2018
-
July 19, 2018
LATEST DATA ON EISAI鈥橲 ALZHEIMER鈥橲 DISEASE / DEMENTIA PIPELINE TO BE PRESENTED AT ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2018
Thirteen presentations to be given including on Phase II study results of BAN2401 and elenbecestat
-
July 18, 2018
EISAI SUPPORTS RELIEF EFFORTS FOR FLOODING IN WESTERN JAPAN
-
July 18, 2018
POSITIVE TOPLINE RESULTS OBTAINED FROM LARGE-SCALE CARDIOVASCULAR OUTCOMES TRIAL OF ANTI-OBESITY AGENT BELVIQ庐
-
July 11, 2018
ORAL ANTIFUNGAL AGENT NAILIN庐 CAPSULES 100MG TO BE LAUNCHED IN JAPAN
-
July 10, 2018
ORAL PRESENTATION ON PHASE II CLINICAL STUDY RESULTS OF BAN2401 TO BE PRESENTED AT ALZHEIMER鈥橲 ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2018
-
July 9, 2018
Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment 鈥淕OOFICE庐 5mg Tablet鈥� Published in The Lancet Gastroenterology & Hepatology
-
July 6, 2018
EISAI AND BIOGEN ANNOUNCE POSITIVE TOPLINE RESULTS OF THE FINAL ANALYSIS FOR BAN2401 AT 18 MONTHS
-
July 4, 2018
EISAI LISTED FOR 17TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
-
July 2, 2018
EISAI TO GIVE ORAL PRESENTATION ON RESULTS OF PHASE III HEAD-TO-HEAD CLINICAL STUDY OF LEMBOREXANT IN INSOMNIA DISORDER AT 43RD ANNUAL MEETING OF THE JAPAN SOCIETY OF SLEEP RESEARCH
AT 鈥淒RUG DISCOVERY RESEARCH FOR SLEEP MEDICINE鈥� SYMPOSIUM
-
June 29, 2018
Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
-
June 21, 2018
EISAI SELECTED FOR MEMBERSHIP IN MSCI JAPAN EMPOWERING WOMEN INDEX (WIN)
-
June 21, 2018
AbbVie and Eisai Announce the Launch of HUMIRA庐 for Subcutaneous Injection 20 mg Syringe 0.2 mL,
A New Pediatric Formulation of HUMIRA庐
-
June 20, 2018
Shelf Registration for Issuance of Stock Options
-
June 20, 2018
Adoption of Resolution for the Partial Revision and Continuation of the 鈥淧olicy for Protection of the Company鈥檚 Corporate Value and Common Interests of Shareholders鈥� (Countermeasures Against Takeovers)
-
June 13, 2018
INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT CONCERNING NUCLEIC ACID DRUG DISCOVERY RESEARCH USING NOVEL NUCLEIC ACID SYNTHESIS AND DELIVERY TECHNOLOGIES CONCLUDED
RESEARCH ACTIVITIES COMMENCE
-
June 13, 2018
EISAI TO ESTABLISH NEW RESEARCH FACILITY 鈥淓ISAI CENTER FOR GENETICS GUIDED DEMENTIA DISCOVERY鈥� IN CAMBRIDGE, MASSACHUSETTS IN THE UNITED STATES
AIMING FOR DRUG DISCOVERY FOCUSED ON IMMUNO-DEMENTIA BASED ON HUMAN GENETICS
-
June 11, 2018
AbbVie and Eisai Announce the Launch of HUMIRA庐 Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-伪 Monoclonal Antibody HUMIRA庐
-
June 6, 2018
Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting
Studies measured postural stability after middle-of-the-night awakening and next morning compared to zolpidem ER, as well as next-morning driving performance
-
June 5, 2018
PHASE II CLINICAL STUDY OF ELENBECESTAT DEMONSTRATES SAFETY AND TOLERABILITY IN MCI AND MILD TO MODERATE ALZHEIMER鈥橲 DISEASE AT 18-MONTHS
RESULTS OF THE PHASE II STUDY DEMONSTRATED A STATISTICALLY SIGNIFICANT DIFFERENCE IN AMYLOID BETA IN BRAIN
-
June 4, 2018
EISAI AND MERCK & CO., INC., KENILWORTH, N.J., U.S.A. ANNOUNCE DATA AT 2018 ASCO ANNUAL MEETING FROM INVESTIGATIONAL STUDIES OF LENVIMA庐 AND KEYTRUDA庐 COMBINATION THERAPY IN FOUR DIFFERENT TUMOR TYPES
-
May 31, 2018
U.S. FDA DESIGNATES FOR PRIORITY REVIEW EISAI鈥橲 SUPPLEMENTAL NEW DRUG APPLICATION FOR ANTIEPILEPTIC DRUG FYCOMPA庐 AS TREATMENT FOR PEDIATRIC PATIENTS WITH EPILEPSY
-
May 28, 2018
PIII Clinical Study Data on Chronic Constipation Treatment 鈥淕OOFICE庐 5mg Tablet鈥� Will Be Presented at DDW2018
-
May 25, 2018
POTENT NEW MECHANISM OF ACTION FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE REVEALED
ORALLY ACTIVE SMALL MOLECULE WITH ANTI-INFLAMMATORY EFFECT DUE TO SUPPRESSION OF INFILTRATION BY LEUKOCYTES INTO INFLAMED SITES
-
May 25, 2018
EISAI AND MERCK & CO., INC., KENILWORTH, N.J., U.S.A. PROVIDE UPDATE ON SUPPLEMENTAL NEW DRUG APPLICATION (sNDA) FOR LENVATINIB IN FIRST-LINE UNRESECTABLE HEPATOCELLULAR CARCINOMA
-
May 23, 2018
EISAI AND PURDUE PHARMA TO PRESENT LATEST PHASE I CLINICAL DATA ON LEMBOREXANT AT 32ND ANNUAL SLEEP MEETING
-
May 17, 2018
EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT 54TH ASCO ANNUAL MEETING
LATEST DATA ON LENVIMA庐 (LENVATINIB) / KEYTRUDA庐 (PEMBROLIZUMAB) COMBINATION THERAPY TO BE PRESENTED
-
April 25, 2018
Partial Revision and Continuation of 鈥淧olicy for Protection of the Company鈥檚 Corporate Value and Common Interests of Shareholders (Countermeasures against Takeovers)鈥�
-
April 23, 2018
RIGHTS TO NON-OPIOID SEVERE CHRONIC PAIN TREATMENT PRIALT庐 TRANSFERRED TO RIEMSER
-
April 20, 2018
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AND RUFINAMIDE AT ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING
-
April 19, 2018
World鈥檚 First Bile Acid Transporter Inhibitor 鈥淕OOFICE庐 5mg Tablet鈥� Launched in Japan
-
April 13, 2018
EISAI ENTERS INTO JOINT RESEARCH AGREEMENT WITH THE BROAD INSTITUTE, COLORADO STATE UNIVERSITY, AND UNIVERSITY OF CHICAGO ON THE DEVELOPMENT OF A POTENTIAL NEW TREATMENT FOR TUBERCULOSIS
-
April 2, 2018
EISAI SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FDA FOR FYCOMPA庐 AS TREATMENT FOR PEDIATRIC PATIENTS WITH EPILEPSY
-
March 30, 2018
Notice Concerning Shelf Registration for Issuance of Stock Options
-
March 30, 2018
RIGHTS TO BOTULINUM TOXIN TYPE B NEUROBLOC庐 IN EUROPE TRANSFERRED TO SLOAN PHARMA, S.脌.R.L.
-
March 30, 2018
ALL-CASE SURVEILLANCE CONDITION FOR APPROVAL OF MULTIPLE SCLEROSIS TREATMENT AVONEX庐 CLEARED IN JAPAN
-
March 28, 2018
EISAI AND NICHI-IKO PHARMACEUTICAL ENTER INTO STRATEGIC ALLIANCE AGREEMENT
-
March 28, 2018
EISAI LAUNCHES REDESIGNED CORPORATE WEBSITE
-
March 23, 2018
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-伪 Monoclonal Antibody HUMIRA庐 in the Treatment of Patients who have had an Inadequate Response to Conventional Therapy for Pustular Psoriasis
-
March 23, 2018
Anticancer Agent LENVIMA庐 Approved for Additional Indication of
Unresectable Hepatocellular Carcinoma (HCC) in Japan,
First Approval Worldwide for LENVIMA for HCC
-
March 14, 2018
EISAI LAUNCHES GASTROINTESTINAL PROKINETIC AGENT CIDINE庐 (CINITAPRIDE HYDROGEN TARTRATE) IN CHINA
-
March 8, 2018
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for
the Fiscal Year Ending March 31, 2018
-
March 8, 2018
缅北禁地. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Enter Global Strategic Oncology Collaboration for LENVIMA庐 (lenvatinib mesylate)
-
March 7, 2018
EISAI AND PURDUE PHARMA ANNOUNCE POSITIVE TOPLINE RESULTS FROM
KEY CLINICAL STUDIES OF LEMBOREXANT
INCLUDING FIRST-EVER PHASE 3 HEAD-TO-HEAD SUPERIORITY COMPARISON
VERSUS ZOLPIDEM ER IN PATIENTS WITH SLEEP DISORDER
-
February 26, 2018
LAUNCH OF 鈥淒EMENTIA SUPPORT鈥� INSURANCE TO PROVIDE FOR DEMENTIA IN JAPAN
-
February 20, 2018
EISAI CERTIFIED IN 2018 AS OUTSTANDING HEALTH AND PRODUCTIVITY MANAGEMENT ORGANIZATION (WHITE 500)
-
February 16, 2018
U.K. NICE RECOMMENDS ANTICANCER AGENT LENVIMA庐 AS TREATMENT FOR THYROID CANCER
-
February 10, 2018
PHASE Ⅲ TRIAL RESULTS OF ANTICANCER AGENT LENVATINIB IN HEPATOCELLULAR CARCINOMA PUBLISHED IN THE LANCET
-
February 9, 2018
EISAI CONTRIBUTES TO TAIWAN EARTHQUAKE RELIEF EFFORTS
-
February 1, 2018
PRIMARY ENDPOINT MET IN PHASE Ⅱ / Ⅲ CLINICAL STUDY OF INVESTIGATIONAL PARKINSON'S DISEASE TREATMENT SAFINAMIDE IN JAPAN
-
January 22, 2018
EISAI PRESENTS RESULTS OF ANALYSIS OF PHASE Ⅲ TRIAL OF LENVIMA庐 (LENVATINIB) IN HEPATOCELLULAR CARCINOMA BASED ON INDEPENDENT IMAGING REVIEW AT ASCO-GI
-
January 19, 2018
New drug approval of bile acid transporter inhibitor 鈥淕OOFICE庐 5mg Tablet鈥� for chronic constipation was obtained in Japan.
-
January 19, 2018
ORAL ANTIFUNGAL AGENT NAILIN庐 CAPSULES 100MG APPROVED IN JAPAN
-
January 19, 2018
EISAI ENTERS INTO LICENSING AGREEMENT WITH ADLAI NORTYE FOR POTENTIAL ANTICANCER AGENT E7046 (PROSTAGLANDIN E2 RECEPTOR TYPE 4 ANTAGONIST)
-
January 18, 2018
PATENT INFRINGEMENT LITIGATION FOR ANTIEMETIC AGENT ALOXI庐 IN THE UNITED STATES
-
January 11, 2018
EISAI COMPLETES CONSTRUCTION OF ORAL SOLID DOSE PRODUCTION FACILITY AT NEW SUZHOU PLANT IN CHINA
-
January 9, 2018
BIOGEN AND EISAI COMMENCE CO-PROMOTION OF MULTIPLE SCLEROSIS TREATMENTS IN JAPAN
-
January 9, 2018
Eisai and Merck & Co., Inc., Kenilworth, N.J., USA. Receive Breakthrough Therapy Designation from U.S. FDA for LENVIMA庐 (lenvatinib mesylate) and KEYTRUDA庐 (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell Carcinoma
